A PHASE-1, OPEN-LABEL, SINGLE-DOSE STUDY OF THE PHARMACOKINETICS OF BUPARLISIB IN SUBJECTS WITH MILD TO SEVERE HEPATIC IMPAIRMENT Article Csonka D., Hazell K., Waldron E., Lorenzo S., Duval V., Trandafir L., Kobalava Z.D. Journal of Clinical Pharmacology. Blackwell Publishing Inc.. Vol. 56. 2016. P. 316-323